Group 1 - The company announced a strategic research and development collaboration and licensing agreement with AstraZeneca, granting AstraZeneca global exclusive rights (excluding Greater China) to the company's weight management product portfolio, including a clinical-ready project SYH2082 and three preclinical projects [1] - The agreement includes an upfront payment of $1.2 billion, potential milestone payments of up to $3.5 billion for research, and up to $13.8 billion for sales, along with a double-digit percentage royalty on annual net sales of the licensed products [1] - This collaboration marks an upgrade in the partnership with AstraZeneca, following previous agreements for the development of Lp(a) small molecule inhibitors and AI-driven oral small molecule drug development, with total potential transaction amounts of $2.02 billion and $5.33 billion respectively [1] Group 2 - The company's core technology platforms are advancing, leading in AI drug discovery and long-acting formulation technology, with a focus on proprietary sustained-release delivery technology and AI drug discovery platform for peptide drugs [2] - The long-acting technology allows for monthly or longer dosing intervals, enhancing patient compliance for long-term medication [2] - The company is building eight innovative technology platforms across multiple disease areas, including oncology, neuropsychiatry, cardiovascular, metabolic, infectious diseases, and autoimmune diseases, with expected net profits of 5.343 billion, 7.869 billion, and 6.761 billion yuan for 2025-2027 [2]
石药集团(01093.HK)：与阿斯利康合作升级 长效多肽全球布局提速